Stem cell therapy

A promising and prospective approach in the treatment of patients with severe buergergss disease

Z. Boda, M. Udvardy, Katalin Rázsó, Katalin Farkas, Judit Tóth, Laszlo Jámbor, Zsolt Oláh, Peter Ilonczai, Mariann Szarvas, J. Kappelmayer, Zoltan Veráb, Eva Rajnavoülgyi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

No effective blood-flow enhancement therapies are available for patients with severe peripheral arterial disease (SPAD), thus amputation remains the only option for relief of rest pain or gangrene. Autologous bone marrowg-derived stem cell therapy (ABMSCT) is an emerging modality to induce angiogenesis from endothelial progenitors. A total of 5 patients with SPAD were treated by ABMSCT using isolated CD34+ cells with characterized phenotype administered by intramuscular injections. The follow-up before and 1, 3, 6, 9, and 12 months after ABMSCT was based on clinical (rest pain, walking distance without pain, nonhealing ulcers, ankle-brachial index [ABI]) and laboratory (angiography, duplex and laser ultrasonography, TcPO2) parameters. Significant improvement of pain and walking distance was observed in all patients. Nonhealing ulcers disappeared in 3 patients and became smaller and thinner in 1 patient. The average of ABI improved significantly on the treated limb but did not change on the contralateral limb. New collaterals were detected by angiography in 3 patients, but duplex ultrasonography detected improvement in one patient only. Laser ultrasonography showed a mild significant change, TcPO2 values improved mainly on the foot. Severe adverse events were not observed. We conclude that ABMSCT with isolated CD34+ cells is safe, effective, and results in sustained clinical benefit for patients with SPAD.

Original languageEnglish
Pages (from-to)552-560
Number of pages9
JournalClinical and Applied Thrombosis/Hemostasis
Volume15
Issue number5
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Peripheral Arterial Disease
Bone and Bones
Pain
Ankle Brachial Index
Ultrasonography
Therapeutics
Ulcer
Walking
Angiography
Lasers
Extremities
Gangrene
Intramuscular Injections
Amputation
Foot
Phenotype

Keywords

  • Autologous bone marrowg- derived stem cell therapy
  • Buergergss disease
  • Nonhealing ulcer
  • Therapeutic angiogenesis

ASJC Scopus subject areas

  • Hematology

Cite this

Stem cell therapy : A promising and prospective approach in the treatment of patients with severe buergergss disease. / Boda, Z.; Udvardy, M.; Rázsó, Katalin; Farkas, Katalin; Tóth, Judit; Jámbor, Laszlo; Oláh, Zsolt; Ilonczai, Peter; Szarvas, Mariann; Kappelmayer, J.; Veráb, Zoltan; Rajnavoülgyi, Eva.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 15, No. 5, 10.2009, p. 552-560.

Research output: Contribution to journalArticle

Boda, Z. ; Udvardy, M. ; Rázsó, Katalin ; Farkas, Katalin ; Tóth, Judit ; Jámbor, Laszlo ; Oláh, Zsolt ; Ilonczai, Peter ; Szarvas, Mariann ; Kappelmayer, J. ; Veráb, Zoltan ; Rajnavoülgyi, Eva. / Stem cell therapy : A promising and prospective approach in the treatment of patients with severe buergergss disease. In: Clinical and Applied Thrombosis/Hemostasis. 2009 ; Vol. 15, No. 5. pp. 552-560.
@article{4b3368a02bc64123803a934d5e3b6456,
title = "Stem cell therapy: A promising and prospective approach in the treatment of patients with severe buergergss disease",
abstract = "No effective blood-flow enhancement therapies are available for patients with severe peripheral arterial disease (SPAD), thus amputation remains the only option for relief of rest pain or gangrene. Autologous bone marrowg-derived stem cell therapy (ABMSCT) is an emerging modality to induce angiogenesis from endothelial progenitors. A total of 5 patients with SPAD were treated by ABMSCT using isolated CD34+ cells with characterized phenotype administered by intramuscular injections. The follow-up before and 1, 3, 6, 9, and 12 months after ABMSCT was based on clinical (rest pain, walking distance without pain, nonhealing ulcers, ankle-brachial index [ABI]) and laboratory (angiography, duplex and laser ultrasonography, TcPO2) parameters. Significant improvement of pain and walking distance was observed in all patients. Nonhealing ulcers disappeared in 3 patients and became smaller and thinner in 1 patient. The average of ABI improved significantly on the treated limb but did not change on the contralateral limb. New collaterals were detected by angiography in 3 patients, but duplex ultrasonography detected improvement in one patient only. Laser ultrasonography showed a mild significant change, TcPO2 values improved mainly on the foot. Severe adverse events were not observed. We conclude that ABMSCT with isolated CD34+ cells is safe, effective, and results in sustained clinical benefit for patients with SPAD.",
keywords = "Autologous bone marrowg- derived stem cell therapy, Buergergss disease, Nonhealing ulcer, Therapeutic angiogenesis",
author = "Z. Boda and M. Udvardy and Katalin R{\'a}zs{\'o} and Katalin Farkas and Judit T{\'o}th and Laszlo J{\'a}mbor and Zsolt Ol{\'a}h and Peter Ilonczai and Mariann Szarvas and J. Kappelmayer and Zoltan Ver{\'a}b and Eva Rajnavo{\"u}lgyi",
year = "2009",
month = "10",
doi = "10.1177/1076029608319882",
language = "English",
volume = "15",
pages = "552--560",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Stem cell therapy

T2 - A promising and prospective approach in the treatment of patients with severe buergergss disease

AU - Boda, Z.

AU - Udvardy, M.

AU - Rázsó, Katalin

AU - Farkas, Katalin

AU - Tóth, Judit

AU - Jámbor, Laszlo

AU - Oláh, Zsolt

AU - Ilonczai, Peter

AU - Szarvas, Mariann

AU - Kappelmayer, J.

AU - Veráb, Zoltan

AU - Rajnavoülgyi, Eva

PY - 2009/10

Y1 - 2009/10

N2 - No effective blood-flow enhancement therapies are available for patients with severe peripheral arterial disease (SPAD), thus amputation remains the only option for relief of rest pain or gangrene. Autologous bone marrowg-derived stem cell therapy (ABMSCT) is an emerging modality to induce angiogenesis from endothelial progenitors. A total of 5 patients with SPAD were treated by ABMSCT using isolated CD34+ cells with characterized phenotype administered by intramuscular injections. The follow-up before and 1, 3, 6, 9, and 12 months after ABMSCT was based on clinical (rest pain, walking distance without pain, nonhealing ulcers, ankle-brachial index [ABI]) and laboratory (angiography, duplex and laser ultrasonography, TcPO2) parameters. Significant improvement of pain and walking distance was observed in all patients. Nonhealing ulcers disappeared in 3 patients and became smaller and thinner in 1 patient. The average of ABI improved significantly on the treated limb but did not change on the contralateral limb. New collaterals were detected by angiography in 3 patients, but duplex ultrasonography detected improvement in one patient only. Laser ultrasonography showed a mild significant change, TcPO2 values improved mainly on the foot. Severe adverse events were not observed. We conclude that ABMSCT with isolated CD34+ cells is safe, effective, and results in sustained clinical benefit for patients with SPAD.

AB - No effective blood-flow enhancement therapies are available for patients with severe peripheral arterial disease (SPAD), thus amputation remains the only option for relief of rest pain or gangrene. Autologous bone marrowg-derived stem cell therapy (ABMSCT) is an emerging modality to induce angiogenesis from endothelial progenitors. A total of 5 patients with SPAD were treated by ABMSCT using isolated CD34+ cells with characterized phenotype administered by intramuscular injections. The follow-up before and 1, 3, 6, 9, and 12 months after ABMSCT was based on clinical (rest pain, walking distance without pain, nonhealing ulcers, ankle-brachial index [ABI]) and laboratory (angiography, duplex and laser ultrasonography, TcPO2) parameters. Significant improvement of pain and walking distance was observed in all patients. Nonhealing ulcers disappeared in 3 patients and became smaller and thinner in 1 patient. The average of ABI improved significantly on the treated limb but did not change on the contralateral limb. New collaterals were detected by angiography in 3 patients, but duplex ultrasonography detected improvement in one patient only. Laser ultrasonography showed a mild significant change, TcPO2 values improved mainly on the foot. Severe adverse events were not observed. We conclude that ABMSCT with isolated CD34+ cells is safe, effective, and results in sustained clinical benefit for patients with SPAD.

KW - Autologous bone marrowg- derived stem cell therapy

KW - Buergergss disease

KW - Nonhealing ulcer

KW - Therapeutic angiogenesis

UR - http://www.scopus.com/inward/record.url?scp=70449640871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449640871&partnerID=8YFLogxK

U2 - 10.1177/1076029608319882

DO - 10.1177/1076029608319882

M3 - Article

VL - 15

SP - 552

EP - 560

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 5

ER -